High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 133-138

  Moreno, Ana ^a   Quereda, Carmen ^a   Moreno, Leonor ^a   Perez Elias, María J ^a   Muriel, Alfonso ^a   Casado, Jose L ^a   Antela, Antonio ^a   Dronda, Fernando ^a   Navas, Enrique ^a   Bárcena, Rafael ^a   Moreno, Santiago ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; DIDANOSINE; LAMIVUDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; DISEASE COURSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERLACTATEMIA; INCIDENCE; LACTIC ACIDOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; NAUSEA; NEUROPATHY; NONBIOLOGICAL MODEL; PARESTHESIA; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DIDANOSINE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PROPORTIONAL HAZARDS MODELS; RIBAVIRIN;

EID: 12144286456     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA & Muñoz A; Multicenter AIDS Cohort Study. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-355.
2. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R & Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases 2001; 32:492-497.
3. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33:1931-1937.
4. Birkus G, Hitchcock MJ & Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy 2002; 46:716-723.
5. Lafeuillade A, Hittinger G & Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
6. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B & Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-1804.
7. Balzarini J, Lee CK, Herdewijn P & De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′ -dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 1991; 266:21509-21514.
8. Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith B, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y & Crumpacker CS. A Phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Journal of Acquired Immune Deficiency Syndromes & Human Retroviruses 1996; 13:235-246.
9. Hor T, Deshayes J, Banisadr F, Pol S, Rosenthal E, Carrat F & Perrone C, on behalf of the ANRS HC02 group. Concomitant ddI/d4T and IFN (standard or pegylated)/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV/HCV infected patients (ANRS HCO2-RIBAVIC study). 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. San Diego, Calif., USA, 27-30 September 2002. Abstract H-1735.
10. Fleischer R, Boxwell D & Sherman KE. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and didanosine. 10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, 10-14 February 2003. Abstract 763.
11. Maxson CJ, Greenfield SM & Turner JL. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome. American Journal of Gastroenterology 1992; 87:708-713.
12. Nguyen BY, Yarchoan R, Wyvill KM, Venzon DJ, Pluda JM, Mitsuy H & Broder S. Five-year follow-up of a Phase I study of didanosine in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases 1995; 171:1180-1189.
13. Pike IM & Nicaise C. The Didanosine Expanded Access Program: safety analysis. Clinical Infectious Diseases 1993; 16(Suppl. 1):S63-S68.
14. Schindzielorz A, Pike I, Daniels M, Pacelli L & Smaldone L. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clinical Infectious Diseases 1994; 19:1076-1083.
15. Foli A, Benvenuto F, Piccinini G, Bareggi A, Cossarizza A, Lisziewicz J & Lori F. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 2001; 15:1687-1694.
16. Falcó V, Rodriguez D, Ribera E, Martínez E, Miró JM, Domingo P, Diazaraque R, Arribas JR, Gonzalez-García JJ, Montero F, Sánchez L & Pahissa A. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clinical Infectious Diseases 2002; 34:838-846.
17. Moore RD, Keruly JC & Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001; 15:617-620.
18. Cihlar T & Chen MS. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases alpha, beta and gamma. Antiviral Chemistry & Chemotherapy 1997; 8:187-195.
19. Kearney BP, Damle B, Plummer A, Sayre J, Zhang X, Ryan K & Cheng AK. Tenofovir DF (TDF) and didanosine EC (ddI EC): investigation of pharmacokinetic (PK) drug-drug and drug-food interactions. XIV International Conference on AIDS. Barcelona, Spain, 7-12 July 2002. Abstract LBPEB9026.
20. Flaherty JF, Kearney BP, Wolf JJ, Sayre JR, Barriere S, Wong S, Wulfsohn M & Coakley DF. Coadministration of tenofovir DF (TDF) and didanosine (ddI): a pharmacokinetic (PK) and safety evaluation. 41st Interscience Conference on Antimicrobial Agents & Chemotherapy. Chicago, Ill., USA, 16-19 December 2001. Abstract I-1729.
21. Kearney BP, Isaacson E, Sayre J, Plummer A & Cheng A. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses & Opportunistic Infections. Boston, Mass., USA, 10-14 February 2003. Abstract 533.
22. Sobue S, Nomura T, Ishikawa T, Ito S, Saso K, Ohara H, Joh T, Itoh M & Kakumu S. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. Journal of Gastroenterology 2001; 36:544-551.